ArticleBMC urology2019

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.

Zhenxing Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.